WealthPLAN Partners’s Neurocrine Biosciences NBIX Stock Holding History

WealthPLAN Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-129	Closed	-$13.1K	–	1346
2023 Q1	$13.1K	Buy	+129	New	+$13.4K	﹤0.01%	802

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WealthPLAN Partners's NBIX Position: Q2 2023 in Review

WealthPLAN Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 129 shares — an estimated $13.1K sold.

WealthPLAN Partners first reported a position in NBIX in Q1 2023 and held it in 1 quarter. The position peaked at $13.1K in Q1 2023. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

WealthPLAN Partners reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
WealthPLAN Partners sold 129 Neurocrine Biosciences shares in Q2 2023, an estimated $13.1K.
WealthPLAN Partners first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 1 quarter.
WealthPLAN Partners's Neurocrine Biosciences position peaked at $13.1K in Q1 2023.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on WealthPLAN Partners's 13F filing for Q2 2023, filed 31 Jul 2023.